The DRAM2 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte cell line. This polyclonal pool encompasses a variety of loss-of-function disruptions in the DRAM2 gene, enabling comprehensive functional analyses while avoiding biases inherent to single-cell clones. The use of CRISPR/Cas9-mediated gene disruption generates a robust and scalable model for studying DRAM2-dependent cellular processes without the need for clonal isolation.
Jurkat cells are a widely utilized human T cell leukemia line originally isolated from a patient with acute lymphoblastic leukemia. They represent a classic model system for investigating T cell receptor signaling, apoptosis, and leukemia biology. The lymphoid origin and malignant phenotype of Jurkat cells provide a physiologically relevant environment for examining autophagy and p53 responses, as these pathways are deeply intertwined with leukemogenesis, immune cell homeostasis, and therapeutic resistance.
DRAM2 is a lysosomal membrane protein transcriptionally upregulated by p53/TP53 in response to DNA damage and stress. It enhances autophagy by promoting lysosomal acidification and autophagosome-lysosome fusion, leading to increased LC3-II lipidation and p62/SQSTM1 degradation. DRAM2 functions downstream of p53 and interacts with lysosomal membrane proteins such as LAMP1, serving as a critical link between p53-dependent stress signaling and autophagic degradation. Its activity is modulated by mTORC1, integrating nutrient sensing with lysosomal function.
In Jurkat leukemic T cells, DRAM2 knockout provides a powerful model to dissect p53-dependent autophagy and its impact on cell survival, DNA damage repair, and drug sensitivity. The impairment of autophagic degradation and lysosomal acidification upon DRAM2 loss allows for investigation of how these defects affect leukemic cell growth and apoptotic responses. With its well-characterized signaling pathways, the Jurkat background facilitates precise analysis of DRAM2??s role in lymphoid malignancies and autophagy-related pathologies.
These polyclonal knockout cells are ideal for monitoring autophagic flux via LC3-II and p62 immunoblotting, assessing lysosomal acidification, and evaluating DNA damage-induced apoptosis by flow cytometry. RT-qPCR can validate p53 target gene expression, and drug sensitivity assays can probe chemotherapeutic responses. The polyclonal nature reduces clonal artifacts and provides a heterogeneous knockout population. For further technical details, contact Ascent Research.
